Pharma / Biotech

Symdeko Indication Broadened to Include CF Patients as Young as 6

The FDA approved the use of tezacaftor-ivacaftor (Symdeko, Vertex) for the treatment of pediatric patients aged 6 years and older who have cystic fibrosis (CF) and certain mutations. Last year, the FDA had approved use of this combination in patients aged 12 years and older with those mutations.

Source link

Related posts

METRONIDAZOLE Gel [NuCare Pharmaceuticals,Inc.]


Chemical and metabolic analysis of Achyranthes bidentate saponins with intestinal microflora-mediated biotransformation by ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry coupled with metabolism platform.


ENTECAVIR Tablet, Film Coated [Amneal Pharmaceuticals LLC]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy